PL217743B1 - Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw - Google Patents

Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw

Info

Publication number
PL217743B1
PL217743B1 PL381823A PL38182305A PL217743B1 PL 217743 B1 PL217743 B1 PL 217743B1 PL 381823 A PL381823 A PL 381823A PL 38182305 A PL38182305 A PL 38182305A PL 217743 B1 PL217743 B1 PL 217743B1
Authority
PL
Poland
Prior art keywords
compound
seizure
stereoisomer
formula
onset
Prior art date
Application number
PL381823A
Other languages
English (en)
Polish (pl)
Other versions
PL381823A1 (pl
Inventor
Annamaria Vezzani
John C.R. Randle
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PL381823A1 publication Critical patent/PL381823A1/pl
Publication of PL217743B1 publication Critical patent/PL217743B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL381823A 2004-05-15 2005-05-16 Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw PL217743B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131404P 2004-05-15 2004-05-15

Publications (2)

Publication Number Publication Date
PL381823A1 PL381823A1 (pl) 2007-07-23
PL217743B1 true PL217743B1 (pl) 2014-08-29

Family

ID=34969808

Family Applications (1)

Application Number Title Priority Date Filing Date
PL381823A PL217743B1 (pl) 2004-05-15 2005-05-16 Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw

Country Status (12)

Country Link
US (2) US20060128696A1 (enExample)
EP (1) EP1750689A1 (enExample)
JP (2) JP4848367B2 (enExample)
CN (2) CN102362867A (enExample)
AU (1) AU2005247409B2 (enExample)
CA (1) CA2566362C (enExample)
IL (1) IL179248A0 (enExample)
MX (1) MXPA06013256A (enExample)
NZ (1) NZ588448A (enExample)
PL (1) PL217743B1 (enExample)
WO (1) WO2005115362A1 (enExample)
ZA (1) ZA200610133B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
JP2009538912A (ja) * 2006-05-31 2009-11-12 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素阻害剤の経口制御放出剤形
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
RU2537361C1 (ru) * 2013-07-18 2015-01-10 Общество С Ограниченной Ответственностью "Синтегал" Оптические изомеры (+) и (-)-бензгидрилмочевин и (+) и (-)-1-[(3-хлорфенил)-фенил-метил]мочевины, фармацевтическая композиция на их основе и способ их получения
ES2985625T3 (es) 2016-03-10 2024-11-06 Orphelia Pharma Formas de dosificación sólidas de vigabatrina
AU2021265849A1 (en) * 2020-05-01 2022-11-24 Medstar Health, Inc. Methods for treating COVID-19
WO2024097731A2 (en) * 2022-11-02 2024-05-10 Medstar Health, Inc. Methods for treating covid-19

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5416013A (en) * 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US6995141B1 (en) * 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
CA2111100C (en) 1991-08-30 2004-11-02 Roy A. Black Interleukin-1 beta protease and interleukin-1 beta protease inhibitors
US5985838A (en) * 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
DK0628550T3 (da) * 1993-06-08 1998-09-28 Vertex Pharma Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer
EP0752987B1 (en) * 1994-03-31 2003-11-12 Vertex Pharmaceuticals Incorporated Pyrimidinyl derivatives as interleukin inhibitors
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6057119A (en) * 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5834514A (en) * 1995-05-30 1998-11-10 Vertex Pharmaceuticals, Incorporated Halomethyl amides as IL-1β protease inhibitors
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
AU738048B2 (en) 1996-09-12 2001-09-06 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
EP0932600B1 (en) 1996-10-11 2006-02-08 Warner-Lambert Company Llc Sulfonamide substituted aspartic acid interleukin-1beta converting enzyme inhibitors
KR20000049048A (ko) 1996-10-11 2000-07-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인터루킨-1β 전환 효소의 아스파르테이트 에스테르 억제제
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
PL332640A1 (en) 1996-10-11 1999-09-27 Warner Lambert Co Sulphonamide-group substituted derivatives of aspartic acid as inhibitors of an interleukin-1beta transforming enzyme
PT944645E (pt) * 1996-12-06 2005-06-30 Vertex Pharma Inibidores da enzima conversora de interleucina 1beta
JP4094066B2 (ja) * 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
DK1049703T3 (da) 1998-01-20 2003-06-02 Abbott Gmbh & Co Kg N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2--(4-fluorphenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-L-asparaginsyrealdehyd som en in vivo inhibitor af interleukin-1beta konverterende enzym
ATE296812T1 (de) * 1998-03-09 2005-06-15 Vertex Pharma 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
WO1999047154A1 (en) 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
RU2274642C2 (ru) * 1998-03-19 2006-04-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы каспаз
AP2000001992A0 (en) 1998-05-05 2000-12-31 Warner Lambert Co Succinamide inhibitors of inteleukin-1B converting enzyme.
EP1084260B1 (en) * 1998-06-02 2007-11-28 Vertex Pharmaceuticals Incorporated Caspase-9 deficient animals and the use thereof
KR20010110667A (ko) 1999-03-16 2001-12-13 추후보정 치환 2-아미노벤즈아미드 카스파제 저해제 및 그것의 용도
MXPA01010127A (es) 1999-04-09 2002-08-20 Cytovia Inc Inhibidores de la caspasa y el uso de los mismos.
AU6894800A (en) * 1999-08-06 2001-03-05 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
KR20020033777A (ko) 1999-08-27 2002-05-07 추후보정 치환된 α-히드록시 산 카스파제 억제제 및 이의 용도
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
CA2389569A1 (en) * 1999-11-16 2001-05-25 Vertex Pharmaceuticals Incorporated Crystallizable compositions comprising a caspase-7
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
DE60132567T2 (de) * 2000-03-29 2009-01-22 Vertex Pharmaceuticals Inc., Cambridge Carbamat caspase inhibitoren und deren verwendung
EP1278737B1 (en) * 2000-04-24 2010-06-30 Vertex Pharmaceuticals Incorporated Process and intermediates for making substituted aspartic acid acetals
NZ520998A (en) * 2000-05-04 2004-11-26 Vertex Pharma Asymmetric synthesis of piperazic acid and derivatives thereof
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US7053057B2 (en) * 2000-05-23 2006-05-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
ES2295171T3 (es) * 2000-06-07 2008-04-16 Vertex Pharmaceuticals Incorporated Inhibidores de caspasa y sus usos.
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
PE20020500A1 (es) 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
JP4349802B2 (ja) * 2000-11-21 2009-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド イミダゾールおよびベンゾイミダゾールカスパーゼのインヒビターならびにそれらの使用
US20030096737A1 (en) * 2001-04-19 2003-05-22 Anita Diu-Hercend Caspase inhibitors and uses thereof
US6875765B2 (en) 2001-05-10 2005-04-05 Warner-Lambert Company Arylsulfonamide ethers, and methods of use thereof
JP4428926B2 (ja) * 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
JP2005509028A (ja) * 2001-10-09 2005-04-07 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
US20030232788A1 (en) 2002-02-08 2003-12-18 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases
EP1485107A1 (en) * 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
WO2004002401A2 (en) 2002-04-05 2004-01-08 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
WO2003088917A2 (en) * 2002-04-19 2003-10-30 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
MXPA05000069A (es) * 2002-06-28 2005-04-11 Vertex Pharma Inhibidores de caspasa y uso de los mismos.
US7612091B2 (en) * 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
JP5129957B2 (ja) 2003-07-03 2013-01-30 ミリアド ジェネティクス， インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
AU2004290413A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
CA2547670A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ice inhibitors
CA2557645C (en) * 2004-02-27 2013-09-24 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
SI2399915T1 (sl) * 2004-03-12 2015-05-29 Vertex Pharmaceuticals Incorporated Postopek in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze
ES2380632T3 (es) * 2004-11-24 2012-05-17 Vertex Pharmceuticals Incorporated Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas
CN101268084A (zh) * 2005-07-28 2008-09-17 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物

Also Published As

Publication number Publication date
WO2005115362A1 (en) 2005-12-08
US20060128696A1 (en) 2006-06-15
ZA200610133B (en) 2008-05-28
CA2566362C (en) 2013-09-10
CA2566362A1 (en) 2005-12-08
AU2005247409A1 (en) 2005-12-08
US20150190404A1 (en) 2015-07-09
CN102362867A (zh) 2012-02-29
CN1980648A (zh) 2007-06-13
JP2011213741A (ja) 2011-10-27
NZ588448A (en) 2012-01-12
IL179248A0 (en) 2008-04-13
MXPA06013256A (es) 2007-02-08
AU2005247409B2 (en) 2011-11-10
PL381823A1 (pl) 2007-07-23
EP1750689A1 (en) 2007-02-14
JP4848367B2 (ja) 2011-12-28
JP2007538013A (ja) 2007-12-27

Similar Documents

Publication Publication Date Title
EP2035029B1 (en) Peptide compounds for treating refractory status epilepticus
US20150190404A1 (en) Treating seizures using ice inhibitors
DE602004007225T2 (de) Methode zur behandlung von erkrankungen der unteren harnwege
TWI397417B (zh) 具有協同抗驚厥功效之醫藥組成物
DeLancey et al. Gross anatomy and cell biology of the lower urinary tract
EP2295054A1 (en) Ice inhibitors for the treatment of autoinflammatory diseases
JP2008539250A (ja) アテローム性動脈硬化症を処置するための方法
RU2193404C2 (ru) Применение левовращающих энантиомеров производных медетомидина
US7098200B2 (en) [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
JP2007538013A5 (enExample)
KR20130048281A (ko) 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도
JP2007506784A (ja) 双極性障害およびその他の認知障害の治療における、ケレリトリン、その類似体およびそれらの使用
KR20210047887A (ko) 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
KR101190529B1 (ko) Ｉｃｅ 억제제를 사용하는 발작의 치료
EP4052702A1 (en) Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
HK1166613A (en) Treating seizures using ice inhibitors
HK1103922A (en) Treating seizures using ice inhibitors
US20060148885A1 (en) Medicinal composition
CN114008013A (zh) 伴有睡眠障碍的cns病症的治疗
JPH04266825A (ja) 睡眠障害の処置剤
HK1107011A (en) Ice inhibitors for the treatment of autoinflammatory diseases
KR20030007314A (ko) 카르프로펜 및 그의 유도체를 포함하는, 포유류에서 관절연골 또는 연골하 골의 초기 단계의 퇴행을 치료 또는예방하기 위한 약학적 조성물 및 팩키지
JPH11240834A (ja) 一過性脳虚血発作抑制剤